Summit Therapeutics Relocates HQ to Miami, FL

Ticker: SMMT · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1599298

Summit Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanySummit Therapeutics Inc. (SMMT)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.01, $186 million
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-governance, administrative-change, 8-K

TL;DR

**Summit Therapeutics moved its main office to Miami.**

AI Summary

Summit Therapeutics Inc. filed an 8-K on January 8, 2024, to report a change in its principal executive offices from 2882 Sand Hill Road, Suite 106, Menlo Park, CA 94025 to 601 Brickell Key Drive, Suite 1000, Miami, FL 33131. This move signifies a relocation of their main operational hub. For investors, this change in address is generally administrative and doesn't directly impact the company's financial performance or strategic direction, but it could signal a shift in operational focus or cost structure over time.

Why It Matters

This filing primarily reports an administrative change of address for Summit Therapeutics Inc.'s principal executive offices, which typically has minimal direct impact on stock value but could reflect broader operational shifts.

Risk Assessment

Risk Level: low — A change in a company's principal executive office address is a routine administrative update and does not inherently carry significant financial or operational risk.

Analyst Insight

Investors should note this administrative change but recognize it typically has no immediate direct impact on the company's fundamentals or stock price. Further investigation might be warranted if this move is part of a larger strategic shift.

Key Players & Entities

  • Summit Therapeutics Inc. (company) — the registrant filing the 8-K
  • 2882 Sand Hill Road, Suite 106, Menlo Park, CA 94025 (address) — former principal executive offices
  • 601 Brickell Key Drive, Suite 1000, Miami, FL 33131 (address) — new principal executive offices
  • January 8, 2024 (date) — date of earliest event reported

FAQ

What is the primary purpose of this 8-K filing by Summit Therapeutics Inc.?

The primary purpose of this 8-K filing is to report a change in the principal executive offices of Summit Therapeutics Inc., as indicated by the 'Date of Earliest Event Reported: January 8, 2024' and the updated address information.

What was Summit Therapeutics Inc.'s former principal executive office address?

Summit Therapeutics Inc.'s former principal executive office address was 2882 Sand Hill Road, Suite 106, Menlo Park, CA 94025, as stated in the filing under 'Former Name or Former Address, If Changed Since Last Report'.

What is Summit Therapeutics Inc.'s new principal executive office address?

Summit Therapeutics Inc.'s new principal executive office address is 601 Brickell Key Drive, Suite 1000, Miami, FL 33131, as listed in the filing under 'Address of Principal Executive Offices'.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 8, 2024, as explicitly stated in the document.

Does this 8-K filing indicate any changes in Summit Therapeutics Inc.'s financial condition or results of operations?

While the filing includes 'ITEM INFORMATION: Results of Operations and Financial Condition' and 'ITEM INFORMATION: Regulation FD Disclosure', the provided text of the 8-K only details the change of address and does not contain specific financial figures or operational results. The primary content available focuses solely on the address change.

Filing Stats: 768 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2024-01-08 09:07:05

Key Financial Figures

  • $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto
  • $186 million — short-term investments was no less than $186 million. This amount is preliminary and is subj

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. As of December 31, 2023, the Company's preliminary unaudited balance of cash, cash equivalents, and short-term investments was no less than $186 million. This amount is preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company's consolidated financial statements for the year ended December 31, 2023. The information in Item 2.02 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 8, 2024, Summit Therapeutics, Inc. (the "Company") issued a press release announcing substantial updates to the development of ivonescimab, as well as near-term corporate catalysts that it will present at the 42nd Annual J.P. Morgan Healthcare Conference. A copy of the press release is attached as Exhibit 99.1 to this current Report on Form 8-K and is incorporated by reference herein. A copy of the presentation is attached as Exhibit 99.2 to this current Report on Form 8-K and is incorporated by reference herein. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.2 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated January 08, 2024 99.2 Investor Presentation Slides made available on January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: January 8, 2024 By: /s/ Ankur Dhingra Chief Financial Officer (Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.